The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian Huntly, PhD.
Sponsored by Novartis US Medical Affairs Elevated lipoprotein(a) (Lp[a]) represents the most common type of genetic dyslipidemia. 1 Elevated Lp(a) levels occurring in 20% of…
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible…
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of hereditary angioedema (HAE) attacks in patients 12 years…
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic…
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
New data shed light on the best strategies for managing patients who develop interstitial lung disease (ILD) while being treated with trastuzumab deruxtecan. City of…
The American Journal of Managed Care News section is a comprehensive resource for clinical news and expert insights. Read more at AJMC.
Five-Year Outcomes With First-Line Nivolumab + Ipilimumab With Chemotherapy vs Chemotherapy in Patients With Metastatic NSCLC in CheckMate 9LA Please see US Full Prescribing Information…
